Synonyms: BMS-986322 | BMS986322 | example 252 [US20210253554]
Compound class:
Synthetic organic
Comment: The chemical structure for lomedeucitinib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a Janus kinase inhibitor with anti-inflammatory potential. This was confirmed by a structure match in PubChem. Lomedeucitinib (BMS-986322) is administered orally. Information provided on BMS' pipeline webpage and other online resources suggests that lomedeucitinib inhibits the JAK family kinase TYK2, which is a recognised driver in systemic/autoimmune immune disorders (via IL-12 and IL-23-mediated TYK2 activation).
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
4-[(3-methylsulfonylpyridin-2-yl)amino]-6-[[(2R)-spiro[2.2]pentane-2-carbonyl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamide |
International Nonproprietary Names | |
INN number | INN |
12982 | lomedeucitinib |
Synonyms |
BMS-986322 | BMS986322 | example 252 [US20210253554] |
Database Links | |
CAS Registry No. | 2328068-29-5 (source: WHO INN record) |
GtoPdb PubChem SID | 491299992 |
PubChem CID | 138620496 |
Search Google for chemical match using the InChIKey | VWIVBQZLVAGLMH-ASGODXDTSA-N |
Search Google for chemicals with the same backbone | VWIVBQZLVAGLMH |
Search PubMed clinical trials | lomedeucitinib |
Search PubMed titles | lomedeucitinib |
Search PubMed titles/abstracts | lomedeucitinib |
UniChem Compound Search for chemical match using the InChIKey | VWIVBQZLVAGLMH-ASGODXDTSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | VWIVBQZLVAGLMH-ASGODXDTSA-N |